Respiratory Infections News

Migrant children who are detained at the U.S. border after seeking asylum are at risk for numerous chronic or acute physical and mental health care conditions, including asthma, dental problems, trauma and infectious diseases. For now, the Trump administration has ended its policy of separating parents from their children as a deterrent against illegal immigration, but experts are concerned that migrant children are not receiving adequate care at detention facilities, and the health implications of their detention and separation can be long-term.

Douglas Jordan

The FDA’s Antimicrobials Drug Advisory Committee has voted in favor of approving Paratek’s new antibiotic omadacycline for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, the company announced.

Children with Down syndrome are more likely to develop severe respiratory syncytial virus, requiring hospitalizations and the use of additional medications and mechanical ventilation, when compared with children without Down syndrome, according to research published in Pediatrics.

Patients newly diagnosed with advanced HIV in Malawi who were screened for tuberculosis with the Xpert MTB/RIF assay had significantly lower rates of 12-month, all-cause mortality than patients who were screened with light-emitting diode fluorescence microscopy, according to recent data from the CHEPETSA trial.

Researchers have determined a link between obesity and the duration of influenza A shedding time in adults, finding it almost doubles the length of virus shedding.

Health care workers with inflammatory bowel disease are at higher risk for tuberculosis infection compared with the general inflammatory bowel disease population, according to research presented in Alimentary Pharmacology & Therapeutics.

Positive topline results have been announced from the phase 2b clinical trial that evaluated an appropriate dose range for RTB101 and demonstrated statistically significant reductions in the incidence of respiratory tract infections.

Although 4 months of treatment with rifampin has comparable safety and efficacy to 9 months of isoniazid for the treatment of latent Mycobacterium tuberculosis infection in children, adherence to treatment was greater among those who were administered rifampin.

Researchers reported in The New England Journal of Medicine that 4 months of rifampin was noninferior to 9 months of isoniazid for the treatment of adults with latent tuberculosis. The shorter regimen was also associated with higher rates of treatment completion and better safety.